Ara
Toplam kayıt 897, listelenen: 881-890
Comparison of the effectiveness of the personalized schroth exercise and conventional therapy for scoliosis in children with rheumatic disease
(BMJ Publishing Group, 2023)
Background: Childhood rheumatic disease is one of the most common chronic diseases in childhood and adolescence [1]. In particular, it causes weakness, pain, problems in the musculoskeletal system, displacement of the ...
Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: A real-life evidence from biostar nationwide registry
(BMJ Publishing Group, 2023)
Background: Association between spondyloarthritis and cardiovascular (CV) diseases is a complex issue with variable outcomes. Objectives: This study aimed to assess the prevalence rates of CV diseases and to analyze the ...
Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: A real-life evidence from biostar nationwide registry
(BMJ Publishing Group, 2023)
Background: Patients with rheumatoid arthritis (RA) have increased morbidity and mortality due to cardiovascular (CV) comorbidities. Objectives: The association of CV diseases (CVD) and traditional CV risk factors have ...
Diffusion-based hierarchical multi-label object detection to analyze panoramic dental X-rays
(Springer Science and Business Media Deutschland GmbH, 2023)
Due to the necessity for precise treatment planning, the use of panoramic X-rays to identify different dental diseases has tremendously increased. Although numerous ML models have been developed for the interpretation of ...
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)
Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ...
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
(American Society of Hematology, 2023)
Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ...
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)
Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ...